Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology

[1]  Daniel Birnbaum,et al.  A gene expression signature identifies two prognostic subgroups of basal breast cancer , 2011, Breast Cancer Research and Treatment.

[2]  N. Kamal,et al.  Factors Affecting Survival of Women Diagnosed with Breast Cancer in El-Minia Governorate, Egypt , 2011, International journal of preventive medicine.

[3]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[4]  S. Cole,et al.  Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study , 2010, Clinical Cancer Research.

[5]  M. Mokni,et al.  Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: a study of 194 patients. , 2010, Pathology, research and practice.

[6]  S. Merajver,et al.  Urban-rural differences in breast cancer incidence in Egypt (1999-2006). , 2010, Breast.

[7]  R. Cress,et al.  Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups? , 2010, Cancer Causes & Control.

[8]  Ayesha Ahmed,et al.  Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study , 2010, BMC Cancer.

[9]  S. Rosso,et al.  New data tells us more about cancer incidence in North Africa. , 2010, European journal of cancer.

[10]  B. Anderson.  Breast cancer hormone receptor status in Egypt: are we asking the questions that matter most? , 2010, Breast Cancer Research and Treatment.

[11]  S. Merajver,et al.  Urban–rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt , 2010, Breast Cancer Research and Treatment.

[12]  C. Perou,et al.  Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[14]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[15]  P. Blasio,et al.  Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa , 2008, Histopathology.

[16]  S. Paik,et al.  Anthracyclines in the treatment of HER2-negative breast cancer. , 2008, Journal of the National Cancer Institute.

[17]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[18]  Daniel Birnbaum,et al.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. , 2006, Cancer research.

[19]  W. Kozlowski,et al.  BRCA1-positive breast cancers in young women from Poland , 2006, Breast Cancer Research and Treatment.

[20]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[21]  R. J. Herrera,et al.  The Levant versus the Horn of Africa: evidence for bidirectional corridors of human migrations. , 2004, American journal of human genetics.

[22]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Lucotte,et al.  Brief communication: Y-chromosome haplotypes in Egypt. , 2003, American journal of physical anthropology.

[24]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[26]  A. Chaudhuri,et al.  HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .

[27]  B Asselain,et al.  Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. , 1998, Anticancer research.